Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma

Video

Georgina Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600­–mutant melanoma.

Georgina Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600­–mutant melanoma.

The COMBI-i study evaluated the combination of spartalizumab, dabrafenib ​(Tafinlar), and trametinib ​(Mekinist), says Long. Findings from parts 1 and 2 of the phase 3 trial were presented during the 2020 ASCO Virtual Scientific Program and showed encouraging clinical activity and tolerability with the novel triplet. 

When using a BRAF inhibitor in combination with a MEK inhibitor, patient biopsies ​often show an influx of T cells within the first week of treatment​, Long explains.

Ultimately, this was the rationale behind the study, ​as the field wanted to determine whether the addition of immunotherapy would induce prolonged, durable responses in this patient population, Long concludes.

Related Videos
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Nikhil A. Gopal, MD
Hans C. Lee, MD
Manish A. Shah, MD
Jobelle Baldonado, MD
Alexey Danilov, MD, PhD,